MannKind’s stock has fluctuated due to Tyvaso DPI’s Q4 underperformance and competitive pressures, but it remains a key revenue driver for future profitability and R&D funding. Tyvaso DPI’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback